The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
Amazon is expanding into GLP-1 medications by carrying oral semaglutide (the Ozempic pill) at U.S. pharmacy kiosks with same-day delivery. This shift could change how millions of Americans access weight and diabetes medications. Here's what you need to know before considering a switch.
A new NIH-funded study found that oral small-molecule GLP-1 drugs can penetrate deep into the brain's reward circuits, suppressing the urge to eat for pleasure in mice. This goes beyond appetite control and points to a fundamentally different way these medications may work. Here's what the research means if you're currently on or considering GLP-1 therapy.
Five new pharmaceutical companies are set to launch competing GLP-1 medications between late 2026 and 2027, with analysts projecting price drops of 40-60%. This means real choices are coming for patients who have been priced out of semaglutide and tirzepatide. Here's what to watch, what to ask your doctor, and how to prepare.
Scientists at Duke University are actively influencing how the next generation of GLP-1 medications gets designed, tested, and approved. For patients currently taking or considering these drugs, understanding where the science is headed can help you make smarter decisions now. Here is what the research means in plain terms.
MyNetDiary has launched a dedicated GLP-1 Companion feature designed for people using semaglutide and tirzepatide medications. This article breaks down what the tool offers, how it compares to other tracking options, and whether it can genuinely help you get better results on your GLP-1 journey.
Canada has approved an additional generic version of Ozempic (semaglutide), marking a significant shift in access to one of the world's most prescribed diabetes and weight-loss medications. This article breaks down what the approval means for Canadian patients, how generic semaglutide compares to the brand-name version, and what to watch for as the market evolves.
A new cohort study found no significant link between GLP-1 medication use around the time of pregnancy and hypertensive disorders. This is important news for women of childbearing age who are using or considering semaglutide or tirzepatide. Here is what the findings mean in plain terms and what you should discuss with your doctor.
When celebrity weight loss sparks Ozempic rumors, the real conversation gets buried. Here's what actually matters for patients considering semaglutide, from medical eligibility to costs and realistic expectations.